News Related to Advancell

Related coverage linked through entity extraction aliases.

Cancer care advances through UAB research and AdvanCell radiopharmaceutical development

Apr 20, 2026

UAB researchers are advancing cancer prevention, tumor targeting and precision ablation, while AdvanCell is developing targeted alpha therapy and a prostate cancer drug in Phase 1 trials. Both efforts focus on new treatment approaches and research infrastructure.

Radioligand Therapy Market Poised for Major Growth Through 2030

Mar 12, 2026

The global radioligand therapy market is projected to grow from $2.6 billion in 2025 to $4.8 billion by 2030 at 13.1% CAGR, driven by FDA label expansions, earlier-line treatment positioning, and substantial private investment in isotope production infrastructure.